Business Wire

XILAM

Share
Spectacular increase in YouTube views (+76%) and revenues (+126%) from Xilam’s catalogue programmes

Regulatory News:

The growth of the audience (number of views) garnered by Xilam’s (Paris:XIL) programmes on YouTube has been accelerating over recent months.

While the number of views rose 21% in 2017, Xilam has seen an impressive 79% increase in the number of views between November 2017 and April 2018, in comparison to the same period last year. Based on this trend, Xilam’s programmes, which were viewed 2.6 billion times on YouTube in 2017, are expected to garner close to 4 billion views in 2018 .

Even more remarkably, revenues over this same six-month period increased 126%. This differential can be explained by a substantial improvement in the monetisation factors.

In addition to the viewing figures, the number of subscribers is also increasing quickly across Xilam’s channels, rising 50% over the same six-month period. Xilam is anticipating reaching close to 5 million total subscribers by the end of 2018 (in comparison to 2.2 million in December 2017). The official Zig and Sharko channel will, by then have reached the same number of subscribers as Oggy & the Cockroaches .

This progress is due to a number of factors:

  • The remarkable work by Xilam’s digital team in managing Xilam’s YouTube channels, creating new channels as well as increasing the volume of content being posted (x3 in comparison to the previous year). The teams have also developed a significant expertise in SEO (Search Engine Optimization).
  • In a number of developed western markets, including the US, the most successful Xilam programmes are included in Google Preferred, the program that aggregates YouTube's top content into easy-to-buy packages for brand advertisers.
  • While revenues made solid gains in Asia-Pacific, they rose even more quickly in North America. This is the result of the recent release of new seasons of Oggy & the Cockroaches and Zig and Sharko on Netflix and Amazon. This massive exposure boost has had a spectacular impact on revenues from YouTube, in particular on the official Zig and Sharko channel which now generates 45% of its revenues in the United States.

Xilam proves to be at the very heart of the digital transformation and the globalisation it is generating. This range of linear and non-linear media is combining forces on a global scale to support Xilam’s premium programmes, and this convergence is benefiting everyone.

This trend will certainly underpin growth in Xilam’s Catalogue revenue.

Marc du Pontavice, Chairman and CEO of Xilam, said: “I am delighted with both the amazing work carried out by Xilam’s teams, and the essential support and guidance provided by our partners at YouTube and YouTube Kids. These platforms enhance the accessibility of Xilam’s programmes worldwide, offering children the chance to have high-quality entertainment at their fingertips .”

Gregory Dray, Director, Head of Kids/Family and Learning, EMEA, Google/YouTube added: “Xilam's universally loved programs have naturally found a unique place on global platforms like YouTube and YouTube Kids. The success of Xilam’s content is a testament to its quality and universality. We are also delighted to see Xilam's commitment to developing a specific expertise in audience development, channel management and programming strategies. As such, the company is well positioned to fully benefit from the rapid growth of YouTube Kids around the world.”

About Xilam

Xilam is one of Europe’s leading animation companies, creating, producing and distributing original children’s and family entertainment content across TV, film and digital media platforms.

Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and three feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons and its first preschool series, Paprika.

Broadcast in over 190 countries on all the major TV networks and digital platforms, in particular garnering over 2.6 billion views on YouTube in 2017, Xilam’s programme catalogue makes the company one of the top global content providers in animation.

Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.

Xilam is listed on Compartment B of Euronext Paris
PEA-eligible
SRD long-eligible
ISIN code: FR0004034072 / Ticker: XIL

86-90, rue Notre-Dame de Nazareth – 75003 PARIS – Tel: +33 (0)1 40 18 72 00 – Fax: +33 (0)1 40 03 02 26
A société anonyme (public limited company) with share capital of EUR 446,500 Paris Trade and Companies Register (RCS): 423 784 610 – SIRET: 423 784 610 00044 – APE 921 A

Contact:

Contacts at Xilam
Marc du Pontavice, +33 1 40 18 72 00
Chairman and CEO
or
Contacts Google/YouTube
Google/YouTube – Press Service
presse-fr@google.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release

Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye